Antigenics, Inc. (Pennsylvania) engages in the development of pharmaceutical products for cancer treatment. The company is headquartered in Horsham, Pennsylvania and currently employs 29 full-time employees. The company went IPO on 2001-07-18. The firm is developing a series of checkpoint modulators (CPM) for the treatment of patients with cancer, infectious diseases, and other immune disorders; heat shock protein (HSP)-based vaccines, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Retrocyte Display (Retroviral B Lymphocyte Display) is an antibody discovery platform designed for the discovery and optimization of fully human and humanized monoclonal antibodies against an array of molecular targets. Its HSP-based vaccine platform includes its Prophage Series vaccine candidates for the treatment of cancer and its HerpV vaccine candidate for the treatment of genital herpes. Its pipeline of product candidates containing QS-21 Stimulon includes vaccines for infectious diseases, cancer types and Alzheimer's disease.
Follow-Up Questions
¿Cuál es el ratio P/E de Antigenics Inc (ANTI)?
El ratio P/E de Antigenics Inc es 0
¿Quién es el CEO de Antigenics Inc?
DR. Geoffrey Cox es el Chairman of the Board de Antigenics Inc, se unió a la empresa desde 1997.
¿Qué tal es el rendimiento del precio de la acción ANTI?
El precio actual de ANTI es de $0, ha decreased un 0% en el último día de negociación.
¿Cuáles son los temas de negocio principales o las industrias de Antigenics Inc?
Antigenics Inc pertenece a la industria N/A y el sector es N/A
¿Cuál es la capitalización bursátil de Antigenics Inc?
La capitalización bursátil actual de Antigenics Inc es $0
